Humacyte 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Humacyte reported 3rd quarter 2026 commercial sales of $1 million, compared with $0.4 million in the 2nd quarter of 2026 and $0.7 million in the 3rd quarter of 2025; sales for the 9 months ended September 30, 2026 were $1.9 million, compared with $1 million in the same period of 2025.
- The number of hospitals ordering SymVes increased 44%, from 34 at the end of the 2nd quarter to 49 at September 30, 2026.
- Research and development expenses were $14.1 million and $51.7 million for the 3 and 9 months ended September 30, 2026, compared with $17.3 million and $54.7 million for the same periods in 2025.
- General and administrative expenses were $9.0 million and $25.0 million for the 3 and 9 months ended September 30, 2026, compared with $7.6 million and $23.6 million for the same periods in 2025.
- Net loss was $15.5 million and $70.0 million for the 3 and 9 months ended September 30, 2026, compared with $17.5 million and $16.0 million for the same periods in 2025.
- Humacyte had cash, cash equivalents, and restricted cash of $64.9 million as of September 30, 2026; net cash used in operating activities was $15.0 million for the 3rd quarter and $62.1 million for the 9 months ended September 30, 2026.
- Cost of goods sold was $1.4 million in the 3rd quarter of 2026, including $0.8 million primarily comprising overhead related to unused production capacity.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the Humacyte Third Quarter 2026 Earnings Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded. I will now turn the call over to Tom Johnson with LifeSci Advisors. Please go ahead. Thank you, operator.
Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which, after filing, may be accessed from the Investor page of the Humacyte website.
Joining me on today's call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer, Jim Mercadante, Chief Commercial Officer, and Dale Sander, Chief Financial Officer and Chief Corporate Development Officer. Dr. Niklason will provide a summary of the company's progress for the third quarter and recent weeks. Jim will provide an update of the commercial transformation and progress with the Symvess market launch, and Dale Sander will review this company's financial results for the quarter ended September 30th, 2026. I will now turn the call over to Dr. Niklason. Laura. Thank you, Tom, and good morning, everyone.
I want to thank you for joining us for our third quarter financial results and business update call. I could not be more excited to share the progress that we're making at Humacyte. What we're doing at Humacyte is exceptionally challenging, and we have created a first-in-class biologic solution that addresses some very significant and broad-based health problems. We have built a team of incredibly talented scientists and other professionals and an outstanding manufacturing facility. I wish that you all had the opportunity to come down and take a tour of our facility. Even representatives from much larger medical device and pharma organizations walk away in awe of what we have built.
I believe that the momentum that we have demonstrated this quarter, along with the upcoming filings and clinical trials, have set the stage for a very significant value creation story in the months and years ahead. It's taken a lot of work to get to this point, and my sincere hope is that we will all look back on today's call as an inflection point for the company. On today's call, after my overview, we'll begin with Jim's review of our commercial progress for Symvess. As you know, Jim was appointed as our Chief Commercial Officer in May, and he's already making a considerable and demonstrable impact on the execution of our commercial strategy. I'll then review progress across our development programs before turning it over to Dale for a review of our financial results for the third quarter.
We'll then be happy to open up the call and take your questions. Let's begin. As we've mentioned previously, our focus for 2026 has been on advancing three main goals: transforming and advancing our commercial programs for Symvess, preparation and submission of our supplemental Biologics License Application, or sBLA, with the FDA for our ATEV product in the dialysis access indication, and commencement of a human study of our coronary tissue-engineered vessels, or CTEVs, in coronary artery bypass grafting. I'm pleased to report that we've made substantial progress on all three of these goals. Commercial adoption of Symvess accelerated during the third quarter, with sales increasing 151% over the second quarter to slightly over $1 million. Our supplemental Biologics License Application, or sBLA, is on track for submission later this month.
We're pleased to announce that we have initiated our first human phase II-A clinical study of CTEV in coronary artery bypass grafting, or CABG, and we are now open and screening patients. I'll now turn the call over to Jim for his review of our commercial results before I recap the progress on our pipeline programs.
Thank you, Laura, and good morning, everyone. It's a pleasure to be speaking with all of you. As I mentioned on the last call, when I joined Humacyte, my immediate focus was to rebuild and reinvigorate our commercial effort for Symvess. I was captivated by the potential to capture meaningful market share in an area where patient outcomes can improve materially. At a baseline level, our revitalized program was designed to drive adoption of the products by hospitals, expand utilization of Symvess, and establish a path to sustained growth for Symvess. To accomplish this, we completely remodeled the commercial team with a focus on ensuring our professionals had critical long-term relationships in the vascular surgery space. Our team has already demonstrated the impact of deep industry relationships and the trust they have built across the market.
We also refined our introductory pricing and incentive programs and approached a peer-to-peer professional education and our focus on hospital adoption. These initiatives were designed to ensure each element worked together to help create a scalable engine that converts interest in our first-in-class product into approvals, utilization, and ultimately sustained revenue growth. I am pleased to report that during our third quarter, the result of this approach is absolutely delivering immediate impact. As Laura mentioned, Symvess sales revenue for the period was $1 million. Our revenue more than doubled from the second quarter, and we achieved our internal goal that we set for the quarter. Hospital adoption also expanded significantly with the number of hospitals ordering Symvess increasing by 44%, from 34 hospitals at the end of second quarter to 49 hospitals at the end of September 30th.
For those of you that understand the challenges of becoming approved as a new provider to a hospital, you can appreciate how excited we are by these results. As momentum has continued into fourth quarter, with October sales now reaching $800,000. With the current levels of hospital adoptions and physician agreement, we are seeing and expect fourth quarter sales to at least double our Q3 results. By the end of the year, we anticipate at least 20 new hospitals to order through our network. Our strategy is delivering results. Our commercial momentum is building, and we believe Symvess is now well-positioned to continue accelerating adoption and driving meaningful, sustainable growth. Like Laura, I am incredibly excited about the outlook for our business. With that, I will turn it back to Laura to review our pipeline.
Thank you, Jim. I'll start with ATEV in dialysis access. Following discussions with the FDA, our plan is to file a sBLA for the ATEV in dialysis access later this month. This sBLA will be supported by results from three phase III clinical studies. Publication of the V007 phase III results in The Lancet Digital Health was very recent in the last few months, and we also recently presented the results of our V012 phase III study in a late-breaking session at the American Society of Nephrology Kidney Week just a few weeks ago. These presentations have given the vascular surgery and nephrology communities an overview of the data that form the basis of our BLA filing. The phase III results on V012 were presented by Prabir Roy-Chaudhury of the University of North Carolina at Chapel Hill, and also a former president of the ASN.
In the V012 phase III trial, women on dialysis treated with the ATEV achieved functional access and use for dialysis more than three months sooner, and spent significantly more time free of dialysis catheters over the first year than did women who received an AV fistula, which is the current standard of care for hemodialysis access. These results also support our belief that the ATEV could represent the first major advance in dialysis access in decades, offering surgeons and patients an alternative option for patients whose risk factors for AV fistula maturation make AV fistula maturation more difficult. As many of you know, we appointed Dr. Prabir Roy-Chaudhury and Dr. Robert Kossmann as advisors to Humacyte. These are leading nephrologists who will help us prepare for the planned commercialization of the ATEV in dialysis access after it's approved by the FDA.
They will also contribute to the development of health economic reimbursement and market access strategies, as well as provide important peer-to-peer scientific support, as they already have, and medical education. Let me turn next to another meaningful opportunity for Humacyte, the CTEV in coronary artery bypass grafting, or CABG. The FDA accepted our investigational new drug application for a first-in-human clinical study of the CTEV in CABG, and we initiated a phase IIa study of the CTEV in CABG patients this month. Also, just this past weekend, three scientific presentations related to CTEV were made at the American Heart Association Scientific Sessions Medical Conference. John Alexander, Professor of Medicine and Cardiology at the Duke Clinical Research Institute, and Alan Kypson, a cardiothoracic surgeon from UNC Rex Hospital, presented an overview of the phase IIa clinical trial protocol for our study.
Researchers from Humacyte also presented preclinical results supporting the progression of the CTEV into the first-in-human study based on extensive large animal results and work. No new off-the-shelf conduits have been introduced for study in CABG in the U.S. in the past 40 years, and our preclinical results suggest that CTEV may be a promising off-the-shelf alternative to saphenous vein grafts. To support this study, we have already completed the first large-scale manufacturing lot of our CTEV product in our commercial-scale manufacturing facilities. With that, it is my pleasure to hand the call over to Dale now for a review of our third quarter financial results. Dale? Thank you, Laura. Commercial sales of Symvess increased to $1 million for the third quarter of 2026, compared to $0.4 million in the second quarter of 2026, and $0.7 million in the third quarter of 2025.
Sequential quarter sales growth and growth compared to the prior year quarter resulted from the commercialization initiatives implemented during the first half of 2026 that Jim described, and an increase in the number of hospitals ordering Symvess during the most recent quarter. For the nine months ended September 30, 2026, commercial sales of Symvess were $1.9 million, compared to $1 million for the nine months ended September 30, 2025. Contract revenue was minimal during the third quarters of 2026 and 2025, and for the nine months ended September 30, 2026, due to the completion of a research project, and was $0.6 million for the nine months ended September 30, 2025.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
